Cardiovascular disease (CVD) is the most common cause of death in NAFLD patients. Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic steatohepatitis (NASH ...

Blood-based biomarkers offer a number of advantages over the traditional standard of fibrosis assessment of liver biopsy ... alcoholic and non-alcoholic fatty liver disease.

Pune, Oct. 18, 2024 (GLOBE NEWSWIRE) -- The SNS Insider report indicates that, “ The Liver Biopsy Market size was about USD 0 ...

As one in three Indians gets diagnosed with non-alcoholic fatty liver, a look at how lifestyle choices can make a difference.

NAFLD doesn’t have any physical symptoms, which makes it virtually impossible to identify without blood tests or a liver ...

Glycated haemoglobin may predict disease severity in patients with NAFLD, a study published in the Diabetes Research and ...

A CAP score of at least 274 dB/m was used to diagnose NAFLD (17, 18). 2.3 Vibration controlled transient elastography (VCTE) A biopsy on the liver remains the gold standard for evaluating hepatic ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Advances in minimally invasive biopsy techniques and the rising incidence of liver disorders, including non-alcoholic fatty liver disease and cirrhosis, are driving market growth. In addition ...